Alexion, The Brigham and Women’s Hospital Inc. deal

ALXN received exclusive worldwide rights to the hospital’s technology covering the Lectin pathway that is involved in complement-mediated inflammation, including a monoclonal antibody that inhibits the pathway. Products could be used to treat atherosclerosis, unstable angina, strokes and other vascular disorders, ALXN said. ...